Go Pro

Extendicare (TSE:EXE) Price Target Cut to C$39.00 by Analysts at Desjardins

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Desjardins lowered Extendicare’s price target to C$39.00 from C$40.00 but maintained a “buy” rating, implying approximately 21.16% upside from the prior close.
  • Analyst sentiment remains positive: Extendicare has an average “Buy” rating and a consensus price target of C$35.44, with recent target increases from BMO, TD, and National Bank Financial.
  • Extendicare shares traded at C$32.19, while the company reported quarterly revenue of C$611.04 million and earnings of C$0.32 per share; its 52-week trading range is C$12.64 to C$39.14.
  • Five stocks to consider instead of Extendicare.

Extendicare (TSE:EXE - Get Free Report) had its price target lowered by analysts at Desjardins from C$40.00 to C$39.00 in a research note issued to investors on Monday,BayStreet.CA reports. The firm presently has a "buy" rating on the stock. Desjardins' price objective points to a potential upside of 21.16% from the stock's previous close.

EXE has been the subject of several other research reports. BMO Capital Markets upped their price target on Extendicare from C$30.00 to C$38.00 in a report on Wednesday, May 13th. TD lifted their price objective on Extendicare from C$32.00 to C$39.00 and gave the stock a "buy" rating in a report on Monday, May 11th. National Bank Financial boosted their price objective on Extendicare from C$34.00 to C$40.00 and gave the company an "outperform" rating in a research report on Wednesday, May 27th. Finally, Canaccord Genuity Group upgraded Extendicare to a "strong-buy" rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of C$35.44.

View Our Latest Analysis on EXE

Extendicare Stock Performance

Extendicare stock traded down C$0.25 during mid-day trading on Monday, reaching C$32.19. The company had a trading volume of 363,614 shares, compared to its average volume of 388,127. The company has a quick ratio of 0.98, a current ratio of 1.44 and a debt-to-equity ratio of 82.55. The firm has a market cap of C$3.05 billion, a price-to-earnings ratio of 23.69 and a beta of 1.59. The company has a 50 day moving average of C$35.24 and a 200-day moving average of C$30.25. Extendicare has a 52 week low of C$12.64 and a 52 week high of C$39.14.

Extendicare (TSE:EXE - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported C$0.32 earnings per share (EPS) for the quarter. Extendicare had a net margin of 6.99% and a return on equity of 45.35%. The company had revenue of C$611.04 million for the quarter. On average, sell-side analysts expect that Extendicare will post 0.6134729 EPS for the current fiscal year.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Further Reading

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines